Tag: stockholder

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Crocs (CROX) To Contact Him Directly To Discuss Their Options

If you purchased or acquired stock in Acadia between February 28, 2020 to October 30, 2024 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648.

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Atkore (ATKR)To Contact Him Directly To Discuss Their Options

Bragar Eagel & Squire, P.C. Litigation Attorneys Encourage Investors Who Suffered Losses In Lockheed (LMT) To Contact The Firm Directly To Discuss Their Options

Bragar Eagel & Squire, P.C. Litigation Attorneys Encourage Investors Who Suffered Losses IRobot (IRBT) To Contact Him Directly To Discuss Their Options

Commack, NY, July 24, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (the “Company”) a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, today announced that its board of directors has approved a bridge funding raise of up to an aggregate amount of $3 million, of which it has secured approximately $1.2 million, through the issuance of shares of the Company’s common stock to institutional or accredited investors.

Company Regains Nasdaq Compliance with Minimum Bid Price Requirement

Carlsbad, CA, July 23, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced an agreement between the Company and several accredited investors to exercise certain existing warrants (the “Existing Warrants”) to purchase up to an aggregate of 4,318,905 shares of common stock. The Existing Warrants had adjusted exercise prices of $1.40 and were issued by the Company on May 10, 2022; February 1, 2024; May 6, 2024; and December 13, 2024, with each exercise occurring at a reduced exercise price of $0.9047 per share.

Second Quarter 2025

HOUSTON, July 23, 2025 (GLOBE NEWSWIRE) -- Crown Castle Inc. (NYSE: CCI) ("Crown Castle") today reported results for the second quarter ended June 30, 2025 and updated its full year 2025 Outlook, as reflected in the table below.

PHOENIX, July 23, 2025 (GLOBE NEWSWIRE) -- Mesa Air Group, Inc. (NASDAQ: MESA) (“Mesa” or the “Company”) announced that it filed a registration statement on Form S-4 and S-1 with the U.S. Securities and Exchange Commission (“SEC”) on July 10, 2025 in connection with the Company's proposed merger (the “Merger”) with Republic Airways Holdings Inc. (“Republic”). The registration statement includes a proxy statement and preliminary prospectus. Once declared effective by the SEC, the final proxy statement/prospectus included in the Form S-4/Form S-1 will be mailed to the Mesa stockholders prior to their vote on the proposed Merger.

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In BellRing Brands (BRBR) To Contact Him Directly To Discuss Their Options

ROCKVILLE, Md., July 22, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report financial and business results for the second quarter of 2025 after the market closes on Tuesday, August 5, 2025.

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In UroGen Pharma (URGN) To Contact Him Directly To Discuss Their Options